Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 1 (2022)
Original paper
Submitted: 2021-05-20
Accepted: 2021-10-21
Published online: 2022-01-24
View PDF Download PDF file
Get Citation

The relationship between chemerin, bone metabolism, the RANKL/RANK/OPG system, and bone mineral density in girls with anorexia nervosa

Zofia Ostrowska1, Małgorzata Morawiecka-Pietrzak2, Wojciech Pluskiewicz3, Elżbieta Świętochowska1, Joanna Strzelczyk1, Karolina Gołąbek1, Jadwiga Gaździcka1, Katarzyna Ziora2
DOI: 10.5603/EP.a2021.0103
·
Pubmed: 35119086
·
Endokrynol Pol 2022;73(1):26-34.
Affiliations
  1. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland, Poland
  2. Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  3. Department and Clinic of Internal Diseases, Diabetology, and Nephrology, Metabolic Bone Diseases Unit, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

open access

Vol 73, No 1 (2022)
Original Paper
Submitted: 2021-05-20
Accepted: 2021-10-21
Published online: 2022-01-24

Abstract

Introduction: Based on recent studies in humans, chemerin has been classified as an adipokine that might be associated with osteoporosis and BMD. Bone loss is common in adolescents with anorexia nervosa (AN). Moreover, dysfunction in the production of chemerin has also been shown. Therefore, we carried out a comparative analysis between chemerin, bone metabolism, the RANKL/RANK/OPG system, and BMD in girls with AN.

Material and methods: Plasma chemerin, OC, CTx, OPG, and sRANKL were determined by ELISA in 75 girls with AN aged 12.6-17.8 years. BMD was assessed by DXA and expressed as Z-score according to the lumbar spine (s) and total body (TB) sites. According to the s-BMD- and TB-BMD Z-score, girls with AN were divided into two subgroups with parallel analyses used: normal (Z-score > –2.0) and low (Z-score ≤ –2.0) s-BMD, and normal (Z-score > –2.0) and low (Z-score ≤ –2.0) TB-BMD.

Results: Mean OC and the OPG/sRANKL ratio were markedly lower in the low s-BMD subgroup compared to the normal s-BMD subgroup. The s-Z-score values (both low and normal) correlated significantly and positively with the OPG/sRANKL ratio. Only in the low s-BMD subgroup did chemerin correlate significantly and positively with all nutritional indices and the OPG/sRANKL ratio. In the low TB-BMD subgroup the mean OC and the OPG/sRANKL ratio were lower than in the normal TB-BMD subgroup. The TB-Z-score values (both normal and low) correlated significantly and positively with all nutritional indices and the OPG/sRANKL ratio. The low TB-Z-score values correlated significantly and positively also with chemerin. In the low TB-BMD subgroup chemerin correlated significantly and positively with weight and BMI (expressed as absolute values), Cole index, the duration of the disease, and OPG/sRANKL ratio while its correlation with age was negative.

Conclusions: Undernutrition and associated deficit of adipose tissue may result in inadequate chemerin production and skeletal disorders in girls with AN. Chemerin acts as a coordinator of the dynamic balance between bone metabolism and the OPG/RANK/RANKL system and, in turn, may contribute to the loss of bone mass in girls with AN. The cortical bone site seems to be more severely responsive to chemerin actions than the trabecular bone site.

Abstract

Introduction: Based on recent studies in humans, chemerin has been classified as an adipokine that might be associated with osteoporosis and BMD. Bone loss is common in adolescents with anorexia nervosa (AN). Moreover, dysfunction in the production of chemerin has also been shown. Therefore, we carried out a comparative analysis between chemerin, bone metabolism, the RANKL/RANK/OPG system, and BMD in girls with AN.

Material and methods: Plasma chemerin, OC, CTx, OPG, and sRANKL were determined by ELISA in 75 girls with AN aged 12.6-17.8 years. BMD was assessed by DXA and expressed as Z-score according to the lumbar spine (s) and total body (TB) sites. According to the s-BMD- and TB-BMD Z-score, girls with AN were divided into two subgroups with parallel analyses used: normal (Z-score > –2.0) and low (Z-score ≤ –2.0) s-BMD, and normal (Z-score > –2.0) and low (Z-score ≤ –2.0) TB-BMD.

Results: Mean OC and the OPG/sRANKL ratio were markedly lower in the low s-BMD subgroup compared to the normal s-BMD subgroup. The s-Z-score values (both low and normal) correlated significantly and positively with the OPG/sRANKL ratio. Only in the low s-BMD subgroup did chemerin correlate significantly and positively with all nutritional indices and the OPG/sRANKL ratio. In the low TB-BMD subgroup the mean OC and the OPG/sRANKL ratio were lower than in the normal TB-BMD subgroup. The TB-Z-score values (both normal and low) correlated significantly and positively with all nutritional indices and the OPG/sRANKL ratio. The low TB-Z-score values correlated significantly and positively also with chemerin. In the low TB-BMD subgroup chemerin correlated significantly and positively with weight and BMI (expressed as absolute values), Cole index, the duration of the disease, and OPG/sRANKL ratio while its correlation with age was negative.

Conclusions: Undernutrition and associated deficit of adipose tissue may result in inadequate chemerin production and skeletal disorders in girls with AN. Chemerin acts as a coordinator of the dynamic balance between bone metabolism and the OPG/RANK/RANKL system and, in turn, may contribute to the loss of bone mass in girls with AN. The cortical bone site seems to be more severely responsive to chemerin actions than the trabecular bone site.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

anorexia nervosa; osteocalcin; CTx; RANKL; OPG; RANK; BMD

About this article
Title

The relationship between chemerin, bone metabolism, the RANKL/RANK/OPG system, and bone mineral density in girls with anorexia nervosa

Journal

Endokrynologia Polska

Issue

Vol 73, No 1 (2022)

Article type

Original paper

Pages

26-34

Published online

2022-01-24

Page views

3292

Article views/downloads

645

DOI

10.5603/EP.a2021.0103

Pubmed

35119086

Bibliographic record

Endokrynol Pol 2022;73(1):26-34.

Keywords

anorexia nervosa
osteocalcin
CTx
RANKL
OPG
RANK
BMD

Authors

Zofia Ostrowska
Małgorzata Morawiecka-Pietrzak
Wojciech Pluskiewicz
Elżbieta Świętochowska
Joanna Strzelczyk
Karolina Gołąbek
Jadwiga Gaździcka
Katarzyna Ziora

References (71)
  1. Keski-Rahkonen A, Mustelin L. Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr Opin Psychiatry. 2016; 29(6): 340–345.
    CrossRefPubMed
  2. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009; 122(5): 409–414.
    CrossRefPubMed
  3. Misra M, Klibanski A. Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord. 2006; 7(1-2): 91–99.
    CrossRefPubMed
  4. Misra M, Klibanski A. Anorexia nervosa and bone. J Endocrinol. 2014; 221(3): R163–R176.
    CrossRefPubMed
  5. Faje AT, Fazeli PK, Miller KK, et al. Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord. 2014; 47(5): 458–466.
    CrossRefPubMed
  6. Misra M, Golden NH, Katzman DK. State of the art systematic review of bone disease in anorexia nervosa. Int J Eat Disord. 2016; 49(3): 276–292.
    CrossRefPubMed
  7. Fazeli PK, Klibanski A. Bone metabolism in anorexia nervosa. Curr Osteoporos Rep. 2014; 12(1): 82–89.
    CrossRefPubMed
  8. Fazeli PK, Klibanski A. Effects of Anorexia Nervosa on Bone Metabolism. Endocr Rev. 2018; 39(6): 895–910.
    CrossRefPubMed
  9. Fazeli PK. Low bone mineral density in anorexia nervosa: Treatments and challenges. Clin Rev Bone Miner Metab. 2019; 17(2): 65–76.
    CrossRefPubMed
  10. Misra M, Klibanski A. The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology. 2011; 93(2): 65–73.
    CrossRefPubMed
  11. Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diab Endocrinol. 2014; 2(7): 581–592.
    CrossRefPubMed
  12. Baskaran C, Misra M, Klibanski A. Effects of anorexia nervosa on the endocrine system. Pediatr Endocrinol Rev . 2017; 14(3): 302–311.
    CrossRefPubMed
  13. Milos G, Hebebrand J. [Endocrine Consequences of Anorexia Nervosa]. Praxis (Bern 1994). 2019; 108(14): 899–904.
    CrossRefPubMed
  14. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab. 2007; 92(6): 2046–2052.
    CrossRefPubMed
  15. Biver E, Salliot C, Combescure C, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96(9): 2703–2713.
    CrossRefPubMed
  16. Liu Y, Song CY, Wu SS, et al. Novel adipokines and bone metabolism. Int J Endocrinol. 2013; 2013: 895045.
    CrossRefPubMed
  17. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015; 64(1): 131–145.
    CrossRefPubMed
  18. Ostrowska Z, Ziora K, Oświęcimska J, et al. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa. Endokrynol Pol. 2014; 65(1): 33–39.
    CrossRefPubMed
  19. Ostrowska Z, Ziora K, Oświęcimska J, et al. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynol Pol. 2015; 66(4): 313–321.
    CrossRefPubMed
  20. Solmi M, Veronese N, Favaro A, et al. Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology. 2015; 51: 237–252.
    CrossRefPubMed
  21. Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab. 1999; 84(12): 4489–4496.
    CrossRefPubMed
  22. Ostrowska Z, Ziora K, Oświęcimska J, et al. RANKL/RANK/OPG system and bone status in females with anorexia nervosa. Bone. 2012; 50(1): 156–160.
    CrossRefPubMed
  23. Ostrowska Z, Ziora K, Oświęcimska J, et al. Vaspin and selected indices of bone status in girls with anorexia nervosa. Endokrynol Pol. 2016; 67(6): 599–606.
    CrossRefPubMed
  24. Gołąbek K, Ostrowska Z, Ziora K, et al. Association between omentin-1, bone metabolism markers, and cytokines of the RANKL/RANK/OPG system in girls with anorexia nervosa. Endokrynol Pol. 2015; 66(6): 514–520.
    CrossRefPubMed
  25. Infante M, Fabi A, Cognetti F, et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019; 38(1): 12.
    CrossRefPubMed
  26. Misra M, Soyka LA, Miller KK, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2003; 88(8): 3816–3822.
    CrossRefPubMed
  27. Muñoz-Calvo MT, Barrios V, García de Alvaro MT, et al. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. Scand J Clin Lab Invest. 2007; 67(4): 387–393.
    CrossRefPubMed
  28. Crabtree NJ, Arabi A, Bachrach LK, et al. International Society for Clinical Densitometry. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014; 17(2): 225–242.
    CrossRefPubMed
  29. Estrada A, Ramnitz MS, Gafni RI. Bone densitometry in children and adolescents. Curr Opin Obstet Gynecol. 2014; 26(5): 339–346.
    CrossRefPubMed
  30. Rauch F, Schoenau E. Changes in bone density during childhood and adolescence: an approach based on bone's biological organization. J Bone Miner Res. 2001; 16(4): 597–604.
    CrossRefPubMed
  31. Milos G, Spindler A, Rüegsegger P, et al. Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos Int. 2005; 16(7): 783–790.
    CrossRefPubMed
  32. Agarwal S, Rosete F, Zhang C, et al. In vivo assessment of trabecular and cortical bone microstructure. Clin Calcium. 2011; 21(7): 1011–1019.
    CrossRefPubMed
  33. Faje AT, Karim L, Taylor A, et al. Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius. J Clin Endocrinol Metab. 2013; 98(5): 1923–1929.
    CrossRefPubMed
  34. Morawiecka-Pietrzak M, Malczyk Ż, Dąbrowska E, et al. Endokrynol Pol. 2021; 72(4): 336–346.
    CrossRefPubMed
  35. de Paula FJ, Rosen CJ. Structure and Function of Bone Marrow Adipocytes. Compr Physiol. 2017; 8(1): 315–349.
    CrossRefPubMed
  36. Muruganandan S, Roman AA, Sinal CJ. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res. 2010; 25(2): 222–234.
    CrossRefPubMed
  37. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282(38): 28175–28188.
    CrossRefPubMed
  38. Muruganandan S, Dranse HJ, Rourke JL, et al. Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis. Stem Cells. 2013; 31(10): 2172–2182.
    CrossRefPubMed
  39. Muruganandan S, Sinal CJ. The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation. IUBMB Life. 2014; 66(3): 147–155.
    CrossRefPubMed
  40. He J, Li JC, Xie H, et al. Serum Chemerin Levels in relation to Osteoporosis and Bone Mineral Density: A Case-Control Study. Dis Markers. 2015; 2015: 786708.
    CrossRefPubMed
  41. Kadric L, Zylla S, Nauck M, et al. Associations Between Plasma Chemerin Concentrations and Bone Quality in Adults From the General Population. Endocrinology. 2018; 159(6): 2378–2385.
    CrossRefPubMed
  42. Menzel J, Biemann R, Aleksandrova K, et al. The cross-sectional association between chemerin and bone health in peri/pre and postmenopausal women: results from the EPIC-Potsdam study. Menopause. 2018; 25(5): 574–578.
    CrossRefPubMed
  43. Engin-Üstün Y, Çağlayan EK, Göçmen AY, et al. Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels. J Menopausal Med. 2016; 22(2): 76–79.
    CrossRefPubMed
  44. Shi L, Mao C, Wang X, et al. Association of chemerin levels and bone mineral density in Chinese obese postmenopausal women. Medicine (Baltimore). 2016; 95(35): e4583.
    CrossRefPubMed
  45. Terzoudis S, Malliaraki N, Damilakis J, et al. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016; 28(7): 814–819.
    CrossRefPubMed
  46. Li Y, Chang J, Jiang T. [Serum level of chemerin and bone mineral density in patients with Graves’ disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017; 42(8): 947–952.
    CrossRefPubMed
  47. Leoni MC, Pizzo D, Marchi A. [Adipocytokines: potential biomarkers for childhood obesity and anorexia nervosa]. Minerva Pediatr. 2010; 62(2): 171–178.
    PubMed
  48. Oświecimska JM, Ziora KT, Suwała A, et al. Chemerin serum levels in girls with anorexia nervosa. Neuro Endocrinol Lett. 2014; 35(6): 490–496.
    PubMed
  49. Gordon CM, Leonard MB, Zemel BS, et al. International Society for Clinical Densitometry. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 2014; 17(2): 219–224.
    CrossRefPubMed
  50. Bachrach LK, Gordon CM. SECTION ON ENDOCRINOLOGY. Bone Densitometry in Children and Adolescents. Pediatrics. 2016; 138(4).
    CrossRefPubMed
  51. Palczewska I, Niedźwiedzka Z. [Somatic development indices in children and youth of Warsaw]. Med Wieku Rozw 2001. 2001; 5(2_Suppl.1): 18–118.
    PubMed
  52. Oświęcimska J, Ziora K, Pluskiewicz W, et al. Ocena gęstości mineralnej kości oraz markerów metabolizmu kostnego u dziewcząt z jadłowstrętem psychicznym. Doniesienie wstępne. Endokrynol Pediatr . 2004; 3(2): 21–32.
  53. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). American Psychiatric Association, Washington 2013.
  54. Morawiecka-Pietrzak M, Ziora K, Ostrowska Z. Interpretation of bone densitometry and definition of osteoporosis in children and adolescents. Pediatr Pol. 2019; 94(4): 241–247.
    CrossRef
  55. Herzog W, Deter HC, Fiehn W, et al. Medical findings and predictors of long-term physical outcome in anorexia nervosa: a prospective, 12-year follow-up study. Psychol Med. 1997; 27(2): 269–279.
    CrossRefPubMed
  56. Brooks ER, Ogden BW, Cavalier DS. Compromised bone density 11.4 years after diagnosis of anorexia nervosa. J Womens Health. 1998; 7(5): 567–574.
    CrossRefPubMed
  57. Oświecimska J, Ziora K, Pluskiewicz W, et al. Skeletal status and laboratory investigations in adolescent girls with anorexia nervosa. Bone. 2007; 41(1): 103–110.
    CrossRefPubMed
  58. Maïmoun L, Guillaume S, Lefebvre P, et al. Role of sclerostin and dickkopf-1 in the dramatic alteration in bone mass acquisition in adolescents and young women with recent anorexia nervosa. J Clin Endocrinol Metab. 2014; 99(4): E582–E590.
    CrossRefPubMed
  59. Kandemir N, Slattery M, Ackerman KE, et al. Bone Parameters in Anorexia Nervosa and Athletic Amenorrhea: Comparison of Two Hypothalamic Amenorrhea States. J Clin Endocrinol Metab. 2018; 103(6): 2392–2402.
    CrossRefPubMed
  60. Seeman E, Karlsson MK, Duan Y. On exposure to anorexia nervosa, the temporal variation in axial and appendicular skeletal development predisposes to site-specific deficits in bone size and density: a cross-sectional study. J Bone Miner Res. 2000; 15(11): 2259–2265.
    CrossRefPubMed
  61. Legroux-Gérot I, Vignau J, D'Herbomez M, et al. Evaluation of bone loss and its mechanisms in anorexia nervosa. Calcif Tissue Int. 2007; 81(3): 174–182.
    CrossRefPubMed
  62. Galusca B, Bossu C, Germain N, et al. Age-related differences in hormonal and nutritional impact on lean anorexia nervosa bone turnover uncoupling. Osteoporos Int. 2006; 17(6): 888–896.
    CrossRefPubMed
  63. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21(11): 660–667.
    CrossRefPubMed
  64. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010; 72(3): 342–348.
    CrossRefPubMed
  65. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161(2): 339–344.
    CrossRefPubMed
  66. Parlee SD, Ernst MC, Muruganandan S, et al. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology. 2010; 151(6): 2590–2602.
    CrossRefPubMed
  67. Yu S, Zhang Y, Li MZ, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl). 2012; 125(19): 3440–3444.
    PubMed
  68. Bobjer J, Katrinaki M, Dermitzaki E, et al. Serum chemerin levels are negatively associated with male fertility and reproductive hormones. Hum Reprod. 2018; 33(12): 2168–2174.
    CrossRefPubMed
  69. Alshaikh EM, Omar UM, Alsufiani HM, et al. The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin. Int J Health Sci (Qassim). 2019; 13(2): 44–47.
    PubMed
  70. Zeng J, Li K, Gong Y, et al. Association of pro-inflammatory cytokines with QCT-measured bone mineral density and its gender difference in a Chinese population - a pilot study. Endokrynol Pol. 2019; 70(3): 248–254.
    CrossRefPubMed
  71. Głogowska-Szeląg J, Kos-Kudła B, Marek B, et al. Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis. Endokrynol Pol. 2019; 70(6): 478–483.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl